Like many GLP-1 medications approved for diabetes, however, weight loss is a side effect of Rybelsus. “Data has shown modest ...

Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much ...

Eli Lilly plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the ...

Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired ...

The 43-year-old retired tennis champ showcased her substantial weight loss in a animal-print teddy over black leggings, ...

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...

Lilly's orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines.

“Semaglutide hits one receptor. It was the first one that came out,” Dr. Howe said. “Tirzepatide hits two receptors, and studies show that with tirzepatide, you get about a 32% weight loss compared to ...

New York City doctors reveals how weight-loss drugs reduce inflammatory cytokines by decreasing fat cells, potentially preventing cancer and autoimmune diseases.

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

The drugmaker has bid for approval for the experimental pill after latest clinical data showed it lowered average blood sugar ...